U-2 OS Whole Cell Lysate

Product Discontinued

U-2 OS Whole Cell Lysate Summary

• Description: Quality control test: 12.5% SDS-PAGE Stained with Coomassie Blue. Whole cell lysate (denatured)
• Localization: Bone
• Preparation Method: Cell lysate was prepared by homogenization in ice-cold modified RIPA Lysis Buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation. Protein concentration was determined with Bradford assay. The lysate was mixed in 5X Sample Buffer to become final Sample Buffer as Storage Buffer. The lysate was heated at 95C for 5 min and cooled rapidly.

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: In ready-to-use Sample Buffer (50 mM Tris-HCl, 2% SDS, 10% Glycerol, 300 mM 2-mercaptoethanol, and 0.01% Bromophenol blue). Lysis Buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF).
• Concentration: 3 mg/ml

Lysate Details for Array

• Type: Cell
• Tissue: Bone/Cartilage
• Protein State: Denatured
• Subcellular Fraction: Whole

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Background

U2OS is a human bone osteosarcoma from a human 15 year old Caucasian female expressing wild type p53 and lacking p16. U2OS also has a ZFN modification creating a GFP-NUP98 transgene expressed from the endogenous NUP98 gene locus. U2OS cells were established in 1964, the original cells were taken from a moderately differentiated sarcoma of the tibia. U2OS cells are positive for insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF II) receptors and express a number of antigens, including blood type A, Rh+, HLA A2, Aw30, B12, Bw35, and B40(+/-).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Lysates are guaranteed for 6 months from date of receipt.